Status: Recruiting
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
Participants needed: 30
Trial details
Phase: Phase 2Age: 1+Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Aug 19, 2026Locations: 23
Eligibility criteria
Age ≥ 1 with a diagnosis of Still's Disease [+6]
Patients out of weight range [+12]